Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine-promising therapeutic strategy for SARS-CoV-2 treatment
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Expert opinion on drug delivery - 17(2020), 12 vom: 21. Dez., Seite 1671-1674 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ansari, Mohammad Azam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 07.05.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1080/17425247.2020.1813712 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313944237 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313944237 | ||
| 003 | DE-627 | ||
| 005 | 20231225151651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17425247.2020.1813712 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM313944237 | ||
| 035 | |a (NLM)32820694 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ansari, Mohammad Azam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine-promising therapeutic strategy for SARS-CoV-2 treatment |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Sars-CoV-2 | |
| 650 | 4 | |a Tat-peptide | |
| 650 | 4 | |a drug delivery | |
| 650 | 4 | |a lipid-based nanocarriers | |
| 650 | 4 | |a outbreak; Nanoformulations | |
| 650 | 4 | |a pandemic | |
| 650 | 4 | |a silver bullet | |
| 650 | 4 | |a vaccine | |
| 700 | 1 | |a Almatroudi, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Alzohairy, Mohammad A |e verfasserin |4 aut | |
| 700 | 1 | |a AlYahya, Sami |e verfasserin |4 aut | |
| 700 | 1 | |a Alomary, Mohammad N |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Dossary, Hanan A |e verfasserin |4 aut | |
| 700 | 1 | |a Alghamdi, Saad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug delivery |d 2004 |g 17(2020), 12 vom: 21. Dez., Seite 1671-1674 |w (DE-627)NLM159019028 |x 1744-7593 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2020 |g number:12 |g day:21 |g month:12 |g pages:1671-1674 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17425247.2020.1813712 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2020 |e 12 |b 21 |c 12 |h 1671-1674 | ||